Increased BDNF expression in fetal brain in the valproic acid model of autism

Molecular and Cellular Neuroscience

Volumn 59, Issue , 2014, Pages 57-62

  Almeida, Luis E F ^a,c   Roby, Clinton D ^a   Krueger, Bruce K ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autism spectrum disorder; Brain development; Brain derived neurotrophic factor; Gene promoters; Neurotrophin; VPA

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NERVE GROWTH FACTOR RECEPTOR; VALPROIC ACID;

ANIMAL; AUTISM; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; EMBRYOLOGY; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; GENETICS; METABOLISM; MOUSE; PREGNANCY; TOXICITY;

ANIMALS; AUTISTIC DISORDER; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; FETUS; MATERNAL-FETAL EXCHANGE; MICE; MICE, INBRED C57BL; PREGNANCY; RECEPTORS, NERVE GROWTH FACTOR; RNA, MESSENGER; VALPROIC ACID;

EID: 84893770848     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2014.01.007     Document Type: Article

References (48)

1. Abrahams B.S., Geschwind D.H. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 2008, 9:341-355.
2. Aid T., Kazantseva A., Piirsoo M., Palm K., Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 2007, 85:525-535.
3. Arndt T.L., Stodgell C.J., Rodier P.M. The teratology of autism. Int. J. Dev. Neurosci. 2005, 23:189-199.
4. Bartkowska K., Paquin A., Gauthier A.S., Kaplan D.R., Miller F.D. Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. Development 2007, 134:4369-4380.
5. Ben-Ari Y. Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders. Trends Neurosci. 2008, 31:626-636.
6. Berg J.M., Geschwind D.H. Autism genetics: searching for specificity and convergence. Genome Biol. 2012, 13:247-263.
7. Binder D.K., Croll S.D., Gall C.M., Scharfman H.E. BDNF and epilepsy: too much of a good thing?. Trends Neurosci. 2001, 24:47-53.
8. Bromley R.L., Mawer G., Clayton-Smith J., Baker G.A. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008, 71:1923-1924.
9. Cha J., Bartos A., Egasira M., Hafraguchi H., Saito-Fugita T., Leishman E., Bradshaw G., Dey S.K., Hirota Y. Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions. J. Clin. Invest. 2013, 123:4063-4075.
10. Chen X., Ye H., Kuruvilla R., Ramanan N., Scangos K.W., Zhang C., Johnson N.M., England P.M., Shokat K.M., Ginty D.D. A chemical-genetic approach to studying neurotrophin signaling. Neuron 2005, 46:13-21.
11. Chomiak T., Hu B. Alterations of neocortical development and maturation in autism: insight from valproic acid exposure and animal models of autism. Neurotoxicol. Teratol. 2013, 36:57-66.
12. Connolly A.M., Chez M., Streif E.M., Keeling R.M., Golumbek P.T., Kwon J.M., Riviello J.J., Robinson R.G., Neuman R.J., Deuel R.M. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol. Psychiatry 2006, 59:354-363.
13. Correia C.T., Coutinho A.M., Sequeira A.F., Sousa I.G., Lourenco Venda L., Almeida J.P., Abreu R.L., Lobo C., Miguel T.S., Conroy J., Cochrane L., Gallagher L., Gill M., Ennis S., Oliveira G.G., Vicente A.M. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav. 2010, 9:841-848.
14. Foley A.G., Gannon S., Rombach-Mullan N., Prendergast A., Barry C., Cassidy A.W., Regan C.M. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology 2012, 63:750-760.
15. Fukumitsu H., Ohtsuka M., Murai R., Nakamura H., Itoh K., Furukawa S. Brain-derived neurotrophic factor participates in determination of neuronal laminar fate in the developing mouse cerebral cortex. J. Neurosci. 2006, 26:13218-13230.
16. Gandal M.J., Edgar J.E., Ehrlichman R.S., Mehta M., Roberts T.P.L., Siegel S.J. Validating γ oscillations and delayed auditory responses as translational biomarkers of autism. Biol. Psychiatry 2010, 68:1100-1106.
17. Gogolla N., Leblanc J.J., Quast K.B., Südhof T.C., Fagiolini M., Hensch T.K. Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J. Neurodev. Disord. 2009, 1:172-181.
18. Huang Y., Doherty J.J., Dingledine R. Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 2002, 22:8422-8428.
19. Kannan G., Sawa A., Pletnikov Mouse models of gene-environment interactions in schizophrenia. Neurobiol. Dis. 2013, 57:5-11.
20. Kolozsi E., Mackenzie R.N., Roullet F.I., Decatanzaro D., Foster J.A. Prenatal exposure to valproic acid leads to reduced expression of synaptic adhesion molecule neuroligin 3 in mice. Neuroscience 2009, 163:1201-1210.
21. Lipina T.V., Zai C., Hlousek D., Roder J.C., Wong A.H.C. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice. J. Neurosci. 2013, 3:7654-7666.
22. Löscher W. Concentration of metabolites of valproic acid in plasma of epileptic patients. Epilepsia 1981, 22:169-178.
23. Maisonpierre P.C., Belluscio L., Friedman B., Alderson R.F., Wiegand S.J., Furth M.E., Lindsay R.M., Yancopoulos G.D. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990, 5:501-509.
24. Markram H., Rinaldi T., Markram K. The intense world syndrome: an alternative hypothesis for autism. Front. Neurosci. 2007, 1:77-96.
25. Meador K.J., Baker G.A., Browning N., Clayton-smith J., Combs-Cantrell D.T., Cohen M., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 2009, 360:1597-1605.
26. Merighi A., Salio C., Ghirri A., Lossi L., Ferrini F., Betelli C., Bardoni R. BDNF as a pain modulator. Prog. Neurobiol. 2008, 85:297-317.
27. Miyazaki K., Narita N., Sakuta R., Miyahara T., Naruse H., Okado N., Narita M. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev. 2004, 26:292-295.
28. Murcia C.L., Gulden F., Herrup K. A question of balance: a proposal for new mouse models of autism. Int. J. Dev. Neurosci. 2005, 23:265-275.
29. Nau H., Löscher W. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and γ-aminobutyric acid (GABA) metabolism in the mouse. J. Pharmacol. Exp. Ther. 1982, 220:654-659.
30. Nelson K.B., Grether J.K., Croen L.A., Dambrosia J.M., Dickens B.F., Jelliffe L.L., Hansen R.L., Phillips T.M. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol. 2001, 49:597-606.
31. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?. Reprod. Toxicol. 2009, 28:1-10.
32. Patterson P.H. Modeling autistic features in animals. Pediatr. Res. 2011, 69:34R-40R.
33. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
34. Ploeger A., Rajimakers M.E., van der Maas H.L., Galis F. The association between autism and errors in early embryogenesis: what is the causal mechanism?. Biol. Psychiatry 2010, 67:602-607.
35. Renoir T., Pang T.Y., Hannan A.J. Effects of environmental manipulations in genetically targeted animal models of affective disorders. Neurobiol. Dis. 2013, 57:12-27.
36. Rodier P.M., Ingram J.L., Tisdale B., Croog V.J. Linking etiologies in humans and animal models: studies of autism. Reprod. Toxicol. 1997, 11:417-422.
37. Roullet F.I., Wollaston L., deCatanzaro D., Foster J.A. Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. Neuroscience 2010, 170:514-522.
38. Schneider T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
39. Schor N.F. The p75 neurotrophin receptor in human development and disease. Prog. Neurobiol. 2005, 77:201-214.
40. State M.W., Levitt P. The conundrums of understanding genetic risks for autism spectrum disorders. Nat. Neurosci. 2011, 14:1499-1506.
41. Stodgell C.J., Ingram J.L., O'Bara M., Tisdale B.K., Nau H., Rodier P.M. Induction of homeotic gene Hoxa1 through valproic acid's teratogenic mechanism of action. Neurotoxicol. Teratol. 2006, 28:617-624.
42. Stoilov P., Castren E., Stamm S. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem. Biophys. Res. Comm. 2002, 290:1054-1065.
43. Surén P., Roth C., Bresnahan M., Haugen M., Hornig M., Hirtz D., Lie K.K., Lipkn W.I., Magnus P., Reichborn-Kjennerud T.R., Schjølberg S., Smith G.D., Øyen A.-S., Susser E., Stolterberg C. Associate between maternal use of folic acid supplements and risk of autism spectrum disorders in children. J. Am. Med. Assoc. 2013, 309:570-577.
44. Szapacs M.E., Mathews T.A., Tessarollo L., ErnestLyons W., Mamounas L.A., Andrews A.M. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J. Neurosci. Methods 2004, 140:81-92.
45. Tsai S.-J. Is autism caused by early hyperactivity of brain-derived neurotrophic factor?. Med. Hypotheses 2005, 65:79-82.
46. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9:519-525.
47. Williams G., King J., Cunningham M., Stephan M., Kerr B., Hersh J.H. Fetal valproate syndrome and autism: additional evidence of an association. Dev. Med. Child Neurol. 2001, 43:202-206.
48. Yasuda S., Liang M.-H., Marinova Z., Yahyavi A., Chuang D.-M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 2009, 14:51-59.